Stents Market Tops $5 Billion, Led by Drug-Eluting Devices
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 11/30/12 -- A growing acceptance of drug-eluting stents as a more effective treatment for coronary heart disease, along with increasing awareness about coronary among patients, is expected to boost procedural volumes. As a result of these factors, the global market for coronary stents is estimated at over $5 billion, according to Kalorama Information's latest report, .
are medical devices developed in the 1980s and introduced to market in the early 1990s as a treatment modality for heart disease. Used in bypass graft surgery and balloon angioplasty, stents prevent the risk of abrupt artery closure and re-narrowing that occurred in many patients following percutaneous coronary interventions. are placed at the site of blockage in the coronary artery, and are kept in it permanently, with the scope of maintaining the artery open, increasing the blood flow to the heart muscle, and preventing restenosis. Currently, there are two major types of coronary stents available in the market: (BMS) and (DES).
"One of the reasons for growth in the market is that the efficacy of drug-eluting stents has been established now, after years of doubt," said Bruce Carlson, Publisher of Kalorama Information. "Increasing disease incidence and new product innovations should drive sales."
Kalorama indicates that the coronary stents industry is a highly competitive one in which innovation occurs rapidly and the technology landscape evolves at a fast pace. The leading players in the coronary stents market in 2011 were Abbott Laboratories, Boston Scientific, and Medtronic. The exit of Cordis Corporation (Johnson & Johnson) from the coronary stents market in 2011, coupled with a series of new product launches in major markets, induced significant shifts in market dynamics.
Kalorama Information's new report, , has further information on this market, including regional sales, segmented sales for bare metal and drug-eluting stents, trends and other business planning information.
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on , and our .
Please direct all media inquiries to:
Bruce Carlson
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.11.2012 - 17:32 Uhr
Sprache: Deutsch
News-ID 208607
Anzahl Zeichen: 4840
contact information:
Town:
NEW YORK, NY
Kategorie:
Hospitals, Facilities and Providers
Diese Pressemitteilung wurde bisher 312 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Stents Market Tops $5 Billion, Led by Drug-Eluting Devices"
steht unter der journalistisch-redaktionellen Verantwortung von
Kalorama Information (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
